Chardan analyst Geulah Livshits raised the firm’s price target on Intellia Therapeutics to $130 from $85 and keeps a Buy rating on the shares. The company reported initial data from the first Phase I trial of a systemic Crisper therapy, NTLA-2001 in transthyretin amyloidosis, demonstrating a “clean” safety profile and a mean reduction in the circulating misfolded transthyretin biomarker of 87% after a one-time dosing, Livshits tells investors in a research note. If durability holds up and no longer-term safety signals emerge, NTLA-2001 “has the potential to be a functional cure for ATTR,” says the analyst. Livshits adds that the results “handily exceed” his base-case expectations for an initial readout, which “now positions NTLA-2001 as a credible contender” in the transthyretin amyloidosis space.